3 results
Primary• To determine the safety profile of oral topotecan in subjects with cancer andmildly moderately or severely impaired renal function (Groups C, D and E) compared to subjects with cancerwhose renal function is normal and who have received…
The objective of this study is to determine the safe and efficacious dose required to eradicate LGD or HGD in BE, or residual BE after endoscopic removal of early cancer (*therapeutic dose*), using the C2 CryoBalloon 180 Ablation System. *Dose* is…
The primary objective is to assess treatment with rovalpituzumab tesirine improves overall survival rate (OS) compared to topotecan in subjects with DLL3high SCLC who have first disease progression during or following front-line platinum based…